Posted by Michael Wonder on 17 Feb 2026
FDA approves Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
17 February 2026 - Johnson & Johnson today announced the US FDA has approved a new, simplified monthly dosing schedule for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj).
When administered in combination with oral Lazcluze (lazertinib) for the first-line treatment of epidermal growth factor receptor mutated advanced non-small cell lung cancer, monthly dosing delivers consistent outcomes with the previously approved bi-weekly subcutaneous dosing schedule.
